Case 1: 2-Year-Old Male With Atopic Dermatitis
Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.
EP: 1.Characteristics of Type 2 Inflammation and the Impact of Itch
EP: 2.Mechanism of Action for Agents Used to Treat Pediatric Atopic Dermatitis
EP: 3.Psychological Impact of Atopic Dermatitis in Pediatric Patients
EP: 4.Presentation and Diagnosis of Atopic Dermatitis in Pediatrics
EP: 5.Burden of Atopic Dermatitis in Pediatric Patients
EP: 6.Pharmacological Options for the Treatment of Pediatric Atopic Dermatitis
EP: 7.Case 1: 2-Year-Old Male With Atopic Dermatitis
EP: 8.Case 1 Continued: Clinical Impressions
EP: 9.Case 1 Continued: Treatments Beyond Topical Agents and the Use of Dupixent
EP: 10.Case 2: 7-Year-Old Female With Atopic Dermatitis
EP: 11.Case 2 Continued: Impressions and Recommendations
EP: 12.Case 2 Continued: Barriers to Treatment Adherence
EP: 13.Case 2 Continued: Importance of Combination Therapy and Shared Decision Making
EP: 14.Case 2 Continued: Addressing Injectable Medication in Children
EP: 15.Case 3: 12-Year-Old-Female With Atopic Dermatitis
EP: 16.Case 3 Continued: Impressions
EP: 17.Case 3 Continued: How to Have Conversation About Risk of Biologics and Length of Therapy
EP: 18.Take-Home Points
Joshua Zeichner, MD: Here’s case No. 1. This is a 2-year-old boy previously diagnosed with moderate atopic dermatitis. He presents to his dermatologist with worsening of red, dry, itchy patches on his arms. The family has taken the child to the pediatrician, who recommended over-the-counter agents. The irritation and redness improved initially, but after 3 months, the patient experienced a flare. The family was then referred to the dermatologist for the next steps.
Transcript edited for clarity
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
Lebrikizumab improves AD symptoms for adolescents inadequately controlled with cyclosporine
October 17th 2023Of the patients that responded to lebrikizumab at week 16 in the phase 3 trials ADvocate 1 and ADvocate 2, 84% achieved a clinically meaningful response in at least 1 domain of the disease (mild signs, symptoms, or quality of life impact) at 52 weeks.
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
October 13th 2023A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
September 21st 2023Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis
September 20th 2023Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
